BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2022 10:23:38 AM | Browse: 491 | Download: 1336
 |
Received |
|
2021-07-22 12:54 |
|
Peer-Review Started |
|
2021-07-22 12:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-11 08:47 |
|
Revised |
|
2021-12-01 19:45 |
|
Second Decision |
|
2022-05-16 03:11 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-17 04:49 |
|
Articles in Press |
|
2022-05-17 04:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-02 00:31 |
|
Publish the Manuscript Online |
|
2022-07-07 10:23 |
| ISSN |
2220-3141(online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Critical Care Medicine |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
David Andaluz-Ojeda, Pablo Vidal-Cortes, Álvaro Aparisi Sanz, Borja Suberviola, Lorena Del Río Carbajo, Leonor Nogales Martín, Estefanía Prol Silva, Jorge Nieto del Olmo, José Barberán and Ivan Cusacovich |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
David Andaluz-Ojeda, MD, PhD, Assistant Professor, Consultant Physician-Scientist, Department of Critical Care, Hospital Universitario HM Sanchinarro, Hospitales Madrid, Oña, 10, Madrid 28050, Spain. davidandaluz78@yahoo.es |
| Key Words |
COVID-19; Critically ill patients; Treatment; Immunomodulary drugs; Phenotype; Immunosupression |
| Core Tip |
Two years after the onset of the pandemic the search for the most appropriate treatment of coronavirus disease 2019 (COVID-19) continues. Few treatments have been evaluated in the context of critically ill patients with COVID-19 considering it in most clinical trials as a negative “end point” of the disease rather than a study subject. This fact makes it extremely difficult to establish degrees of recommendation regarding the different therapeutic options currently available. This review aims to summarize the immunopathogenesis and the current evidence regarding the different immunomodulatory strategies tested in critically ill patients with COVID-19. In addition, the presence of different immunophenotypes that in the future will serve as a basis for individualized treatments is demonstrated. |
| Publish Date |
2022-07-07 10:23 |
| Citation |
Andaluz-Ojeda D, Vidal-Cortes P, Aparisi Sanz Á, Suberviola B, Del Río Carbajo L, Nogales Martín L, Prol Silva E, Nieto del Olmo J, Barberán J, Cusacovich I. Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. World J Crit Care Med 2022;11(4): 269-297 |
| URL |
https://www.wjgnet.com/2220-3141/full/v11/i4/269.htm |
| DOI |
https://dx.doi.org/10.5492/wjccm.v11.i4.269 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
